Stocktoria

Alzamend Neuro, Inc. ALZN

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-06-15 · LEI

Alzamend Neuro, Inc. statistics & valuation

Market cap$4.6M
P / B6.2×

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2020202120222023202420252026
Operating margin (%)
2020202120222023202420252026
Return on equity (%)
-536.70% -250.70% -92.60% -488.50% -113.80% -1196.40% 2020202120222023202420252026
Shares outstanding
64.8M 72.7M 95.5M 650126 76444 778733 4.3M 2020202120222023202420252026
Net debt ($)
2020202120222023202420252026
Share buybacks ($)
2020202120222023202420252026
Return on assets (%)
-243.10% -173.30% -85.20% -251.50% -1575.00% -98.10% -421.90% 2020202120222023202420252026
Free cash flow margin (%)
2020202120222023202420252026
Debt / equity (×)
2020202120222023202420252026
EPS ($)
-$0.14 -$22.89 -$132.33 -$11.32 -$2.63 2020202120222023202420252026

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2026FY2025FY2024FY2023FY2022FY2021FY2020
Return on assets-421.9%-98.1%-1575.0%-251.5%-85.2%-173.3%-243.1%
Return on equity-1196.4%-113.8%383.5%-488.5%-92.6%-250.7%-536.7%
Current ratio———2.0312.373.241.83

Computed from company filings · US · as of 2025-04-30. Facts plus Stocktoria's own computed scores — not investment advice.